BETHLEHEM, PA--(Marketwired - Jul 11, 2016) -  B. Braun Medical Inc., a leader in infusion therapy and pain management, announced today that it has launched its new 500mg Meropenem for Injection USP and Sodium Chloride Injection USP and 1g Meropenem for Injection USP and Sodium Chloride Injection USP in the company's DUPLEX® container.

The addition of Meropenem expands B. Braun's offering of intravenous antibiotic therapies in the DUPLEX container, which is designed to simplify intravenous delivery to patients. The company also offers a full line of cephalosporin's in the DUPLEX container.

"The launch of Meropenem in our innovative DUPLEX container eliminates the need for healthcare providers to compound or batch Meropenem vials, which can save time, reduce drug waste, and minimize the potential for medication errors," said Rick Williamson, Vice President of Pharmaceutical Marketing at B. Braun.

The DUPLEX container consists of a pre-filled, flexible plastic IV bag containing proper doses of drug -- such as Meropenem -- and diluent in two different compartments separated by a quick release seal. The caregiver simply squeezes the bag to mix the drug and diluent just prior to administration.

The container, which can be stored at room temperature in an automated dispensing cabinet in healthcare settings, is designed to save time, reduce labor, and speed dispensing. Additionally, it is not made with natural rubber latex, or with Di-ethylhexyl phthalate (DEHP) or Polyvinyl Chloride (PVC), both of which present risk to patients and the environment. A barcode that references the final admixture, lot number, and expiration date helps reduce medication errors, automate patient charting, track inventory, and facilitate reimbursement tracking.

To learn more about the DUPLEX container, as well as B. Braun's full drug delivery portfolio, click here or call 1-888-422-7286.

About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is part of the B. Braun Group of Companies in the U.S., which is headquartered in Bethlehem, Pa., and includes B. Braun Interventional Systems, Aesculap® and CAPS®.

Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit

Contact Information:

Jason Ford
B. Braun Medical Inc.